Related Experiment Videos
Human interferon-beta therapy for cerebral primitive neuroectodermal tumors--two case reports
S Tanaka1, M Okada, M Murakami
1Department of Neurosurgery, Ichihara Hospital, Teikyo University School of Medicine, Chiba, Japan.
Insights
Human fibroblast interferon (HuIFN-beta) shows promise in treating recurrent pediatric primitive neuroectodermal tumors (PNET). This interferon therapy may offer an effective, low-side-effect option for long-term PNET maintenance.
Area of Science:
- Pediatric Oncology
- Immunotherapy
- Neuro-oncology
Background:
- Recurrent pediatric primitive neuroectodermal tumors (PNET) present significant treatment challenges.
- Limited effective long-term maintenance therapies exist for PNET.
Observation:
- Two pediatric patients with recurrent PNET received intravenous human fibroblast interferon (HuIFN-beta).
- Treatment was continued as outpatient maintenance therapy.
Findings:
- Both patients demonstrated a partial response to HuIFN-beta therapy.
- Patients remained alive 14 months and 2 years post-diagnosis, indicating sustained efficacy.
Implications:
- HuIFN-beta may be an effective therapeutic option for pediatric PNET.
- This immunotherapy can potentially be used for long-term PNET maintenance with minimal adverse effects.
Abstract:
A 5-year-old girl and a 2-year-old boy presented with recurrent cerebral primitive neuroectodermal tumor (PNET) and were treated with intravenous administration of human fibroblast interferon (HuIFN-beta) which was continued as outpatient maintenance therapy. Both patients showed a partial response and were still alive 14 months and 2 years after diagnosis. Our results suggest that HuIFN-beta is an effective therapy for PNET, and can be used as long-term maintenance therapy without serious side effects.